Genetic variation of estrogen metabolism and the risks of cardiovascular disease

Current Opinion in Investigational Drugs

Volumn 8, Issue 10, 2007, Pages 814-820

  Almeida, S ^a   Hutz, M H ^b  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cardiovascular disease; Estrogen metabolism; Estrogen receptor; Genetic variant; Hormonal replacement therapy; Pharmacogenetics

Indexed keywords

4 HYDROXYESTRADIOL; ANDROSTENEDIONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CYTOCHROME P450 19A1; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME MAP; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; ESTROGEN METABOLISM; ESTROGEN THERAPY; EXON; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HEART INFARCTION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYDROXYLATION; INFLAMMATION; INSULIN BLOOD LEVEL; INTRON; LIPID BLOOD LEVEL; MENOPAUSAL SYNDROME; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PHENOTYPE; POSTMENOPAUSE; RECEPTOR GENE; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

CARDIOVASCULAR DISEASES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK; RISK FACTORS;

EID: 34848826824     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Miller VM, Shuster LT, Hayes SN: Controversy of hormone treatment and cardiovascular function: Need for strengthened collaborations between preclinical and clinical scientists. Curr Opin Investig Drugs (2003) 4(10):1220-1232.
2. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med (1999) 340(23):1801-1811.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc (1998) 280(7):605-613. • This was the first randomized trial to consider the clinical cardiovascular effect of HRT in postmenopausal women with established CVD.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc (2002) 288(3):321-333. • This is the largest prospective randomized controlled trial of clinical cardiovascular effects of HRT in healthy postmenopausal women.
5. Herrington DM, Klein KP: Invited review: Pharmacogenetics of estrogen replacement therapy. J Appl Physiol (2001) 91(6):2776-2784.
6. Herrington DM, Howard TD: ER-α variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics (2003) 4(3):269-277.
7. Deroo BJ, Korach KS: Estrogen receptors and human disease. J Clin Invest (2006) 116(3):561-570. •• This review describes diseases in which estrogen, via action at ERs, plays a role in the development or severity of disease.
8. Green S, Walter P, Kumar V, Krust A, Bornert J-M, Argos P, Chambon P: Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-I. Nature (1986) 320(6058):134-139.
9. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA: Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab (1997) 82(12):4258-4265.
10. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation (1994) 89(4):1501-1510.
11. Ferrero V, Ribichini F, Matullo G, Guarrera S, Carturan S, Vado A, Vassanelli C, Piazza A, Uslenghi E, Wijns W: Estrogen receptor-α polymorphisms and angiographic outcome after coronary artery stenting. Arterioscler Thromb Vasc Biol (2003) 23(12):2223-2228.
12. Nordström P, Glader CA, Dahlén G, Birgander LS, Lorentzon R, Waldenström A, Lorentzon M: Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med (2003) 254(2):140-146.
13. Lu H, Higashikata T, Inazu A, Nohara A, Yu W, Shimizu M, Mabuchi H: Association of estrogen receptor-α gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2002) 22(5):817-823.
14. Koivu TA, Fan YM, Mattila KM, Dastidar P, Jokela H, Nikkari ST, Kunnas T, Punnonen R, Lehtimäki T: The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas (2003) 44(1):29-38.
15. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D: Association between estrogen receptor α gene variation and cardiovascular disease. J Am Med Assoc (2003) 290(17):2263-2270.
16. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG: Estrogen receptor α gene polymorphisms and risk of myocardial infarction. J Am Med Assoc (2004) 291(24):2969- 2977.
17. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Grønholdt ML, Grande P, Jensen GB, Nordestgaard BG: Estrogen receptor α polymorphism and risk of cardiovascular disease, cancer, and hip fracture: Cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation (2007) 115(7):861-871. •• This paper reviews the main findings of association studies between the ESR1 gene and several diseases (mainly CVD).
18. Demissie S, Cupples LA, Shearman AM, Gruenthal KM, Peter I, Schmid CH, Karas RH, Housman DE, Mendelsohn ME, Ordovas JM: Estrogen receptor-α variants are associated with lipoprotein size distribution and particle levels in women: The Framingham Heart Study. Atherosclerosis (2006) 185(1):210-218.
19. Shearman AM, Demissie S, Cupples LA, Peter I, Schmid CH, Ordovas JM, Mendelsohn ME, Housman DE: Tobacco smoking, estrogen receptor α gene variation and small low density lipoprotein level. Hum Mol Genet (2005) 14(16):2405-2413.
20. de Padua Mansur, Nogueira CC, Strunz CM, Aldrighi JM, Ramires JA: Genetic polymorphisms of estrogen receptors in patients with premature coronary artery disease. Arch Med Res (2005) 36(5):511-517.
21. Sowers MR, Symons JP, Jannausch ML, Chu J, Kardia SR: Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women's Health Across the Nation (SWAN). Am J Med (2006) 119(9 Suppl 1):S61-S68.
22. Huang Q, Wang TH, Lu WS, Mu PW, Yang YF, Liang WW, Li CX, Lin GP: Estrogen receptor α gene polymorphism associated with type 2 diabetes mellitus and the serum lipid concentration in Chinese women in Guangzhou. Chin Med J (Engl) (2006) 119(21):1794-1801.
23. Molvarec A, Nagy B, Kovács M, Walentin S, Imreh E, Rigó J Jr, Szalay J, Füst G, Prohászka Z, Karádi I: Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor α (ESR1) PvuII and XbaI gene polymorphisms. Clin Chim Acta (2007) 380(1-2):157-164.
24. Rokach A, Pollak A, Rosen L, Friedlander Y, Blumenfeld A, Reznik L, Dresner-Pollak R: Estrogen receptor α gene polymorphisms are associated with the angiographic extent of coronary artery disease. J Clin Endocrinol Metab (2005) 90(12):6556-6560.
25. Almeida S, Hutz MH: Estrogen receptor 1 gene polymorphisms and coronary artery disease in the Brazilian population. Braz J Med Biol Res (2006) 39(4):447-454.
26. Lussana F, Faioni EM, Mavilia C, Bucciarelli P, Brandi ML, Cattaneo M: Association of estrogen receptor-α gene polymorphisms with venous thrombosis. Haematologica (2006) 91(2):279-280.
27. Koch W, Hoppmann P, Pfeufer A, Mueller JC, Schömig A, Kastrati A: No replication of association between estrogen receptor α gene polymorphisms and susceptibility to myocardial infarction in a large sample of patients of European descent. Circulation (2005) 112(14):2138- 2142.
28. de Maat MP, Bladbjerg EM, Kluft C, Winkler UH, Rekers H, Skouby SO, Jespersen J: Estrogen receptor 1 haplotype does not regulate oral contraceptive-induced changes in haemostasis and inflammation risk factors for venous and arterial thrombosis. Hum Reprod (2006) 21(6):1473-1476.
29. Newton-Cheh C, O'Donnell CJ: Sex differences and genetic associations with myocardial infarction. J Am Med Assoc (2004) 291(24):3008-3010.
30. Shearman AM, Cooper JA, Kotwinski PJ, Miller GJ, Humphries SE, Ardlie KG, Jordan B, Irenze K, Lunetta KL, Schuit SC, Uitterlinden AG et al: Estrogen receptor α gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res (2006) 98(5):590-592.
31. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan B, Meyers DA, Bleecker ER: Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med (2002) 346(13):967-974.
32. Swartz CD, Afshari CA, Yu L, Hall KE, Dixon D: Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod (2005) 11(6):441-450.
33. Almeida S, Fiegenbaum M, de Andrade FM, Osório-Wender MC, Hutz MH: ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy. Maturitas (2006) 54(2):119-126.
34. Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML: Estrogen receptor α and β polymorphisms: Is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause (2006) 13(3):451-461.
35. Hall WL, Vafeiadou K, Hallund J, Bugel S, Reimann M, Koebnick C, Zunft HJ, Ferrari M, Branca F, Dadd T, Talbot D et al: Soy-isoflavone- enriched foods and markers of lipid and glucose metabolism in postmenopausal women: Interactions with genotype and equol production. Am J Clin Nutr (2006) 83(3):592-600.
36. Lawlor DA, Timpson N, Ebrahim S, Day IN, Smith GD: The association of oestrogen receptor α-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study. Eur Heart J (2006) 27(13):1597-1604.
37. Kajinami K, Brousseau ME, Lamon-Fava S, Ordovas JM, Schaefer EJ: Gender-specific effects of estrogen receptor α gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: Interaction with apolipoprotein AI gene polymorphism. Atherosclerosis (2005) 178(2):331-338.
38. Rosenkranz K, Hinney A, Ziegler A, Hermann H, Fichter M, Mayer H, Siegfried W, Young JK, Remschmidt H, Hebebrand JH: Systematic mutation screening of the estrogen receptor β gene in probands of different weight extremes: Identification of several genetic variants. J Clin Endocrinol Metab (1998) 83(12):4524-4527.
39. Almeida S, Franken N, Zandoná MR, Osório-Wender MC, Hutz MH: Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J (2005) 5(1):30-34.
40. Lin PI, Vance JM, Pericak-Vance MA, Martin ER: No gene is an island: The flip-flop phenomenon. Am J Hum Genet (2007) 80(3):531-538.
41. Arko B, Prezelj J, Komel R, Kocijancic A, Marc J: No major effect of estrogen receptor β gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2002) 81(2):147-152.
42. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet (2003) 12(3):205-216.
43. Dubey RK, Jackson EK: Cardiovascular protective effects of 17β-estradiol metabolites. J Appl Physiol (2001) 91(4):1868-1883. • The effects of estrogen metabolites on the cardiovascular system are reported and discussed in this paper.
44. Neven P: The origin of postmenopausal oestrogens. Eur J Cancer (2002) 38(Suppl 6):S29-S30.
45. Badawi AF, Cavalieri EL, Rogan EG: Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16α-hydroxylation of 17β-estradiol. Metabolism (2001) 50(9):1001-1003.
46. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology (2003) 144(8):3382-3398. •• In this paper, the oxidative metabolites of 17 β-estradiol and estrone formed by 15 human CYP isoforms are characterized. Many human CYP isoforms are involved in the oxidative metabolism of endogenous estrogen, with a varying degree of catalytic activity and distinct regioselectivity.
47. Matsui A, Ikeda T, Enomoto K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M: Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-Omethyltransferase. Cancer Lett (2000) 150(1):23-31.
48. Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, Lee K, Acevedo C, Martínez L, Aguilera AM, Gil L: CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett (2001) 174(1):35-44.
49. Almeida S, Zandoná MR, Franken N, Callegari-Jacques SM, Osório-Wender MC, Hutz MH: Estrogen-metabolizing gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J (2005) 5(6):346-351. •• This paper was the first to suggest that estrogen-metabolizing genes might be associated with lipid levels and CVD.
50. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (1998) 90(16): 1225-1229.
51. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther (2003) 74(3):245-254.
52. Hayashi S, Watanabe J, Nakachi K, Kawajiri K: PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res (1991) 19(17):4797.
53. Garte S: The role of ethnicity in cancer susceptibility gene polymorphisms: The example of CYP1A1. Carcinogenesis (1998) 19(8):1329-1332.
54. Zhu BT, Conney AH: Functional role of estrogen metabolism in target cells: Review and perspectives. Carcinogenesis (1998) 19(1):1-27.